

**Institutional Biosafety
Committee Minutes
July 10, 2025
Zoom Meeting 1:30 pm**

Members Present

Hugh Mason
Al Jensen
Drew Solomon
Christopher Plaisier
Mitch Magee
Kathleen Kennedy
Valerie Stout
Greg Powell*

Affiliated Participants

Amanda Rice
Mary Turlington-Powell
Suzanne Kennedy
Karen Stevenson
Sarah Hurd

Visitors Present

Wendy Winslow
Alexis Weston
Xu Wang
Glen DSouza

Supporting Participants

Bree Prinzhorn
Kristy Macdonald
Samantha Sullivan

Note: * Denotes Alternate Biosafety Officer

Note: This meeting was conducted via Zoom. Meeting Format: Open meeting

Call to Order: The Alternate IBC Chair called the meeting to order at 1:30 pm and a quorum was confirmed. Introductions were made.

Minutes

The meeting minutes from June 12, 2025, were reviewed by the committee. A motion was made to approve the minutes as presented. The motion was seconded.

Total Vote: 8 Approved: 8 Opposed: 0 Abstained: 0 Recused: 0

Conflicts of Interest

The Alternate IBC Chair called for conflicts. No conflicts were reported.

Disclosures for Committee Review:

Velazquez SPROTO2025-48 (BSL2 Renewal)

Velazquez deciphering the underlying molecular mechanisms in AD

Primary Reviewer: Mitch Magee

The lab manager provided an overview of the disclosure and responded to questions posed by the committee members. The lab is conducting research on Alzheimer's Disease and neurodegenerative disorders. The following changes were administratively made to the disclosure:

- Unchecked sections III-D-4-c (1), III-F-2, and III-F-8, Appendix C-VIII on the NIH Guidelines page.
- Checked sections III-D-4 and III-D-4-a on the NIH Guidelines page.

Discussion confirmed that Biosafety Level 2 precautions, training, and personal protective equipment are appropriate as proposed. Based on committee discussion, the NIH Guidelines classification for this disclosure was determined to be sections III-D, III-D-4, III-D-4-a, III-D-4-c, III-D-4-c (2), III-E, III-E-1, III-E-3, III-F-1, and III-F-

8, Appendices C-I, C-II, and C-VII. A motion was made to approve the disclosure as modified. The motion was seconded.

Total Vote: 8 Approved: 8 Opposed: 0 Abstained: 0 Recused: 0

Sharma SPROTO2025-33 (BSL2 New Disclosure)

HRI Sharma Lab IBC

Primary Reviewer: Chris Plaisier

The lab manager provided an overview of the disclosure and responded to questions posed by the committee members. The lab is conducting research on development of novel therapeutics intended for clinical use. The following changes were administratively made to the disclosure:

- Unchecked sections III-E-1 and III-F-8, Appendix C-VIII on the NIH Guidelines page.
- Added E. coli BL21 to Question 8 on the Recombinant or Synthetic Nucleic Acid Work Description Page.

Discussion confirmed that Biosafety Level 2 precautions, training, and personal protective equipment are appropriate as proposed. Based on committee discussion, the NIH Guidelines classification for this disclosure was determined to be sections III-D, III-D-3, III-D-3-a, III-D-4, III-D-4-a, III-E, III-F-1, and III-F-8, Appendices C-I and C-VII. A motion was made to approve the disclosure as modified. The motion was seconded.

Total Vote: 8 Approved: 8 Opposed: 0 Abstained: 0 Recused: 0

Wang, Xu SPROTO2025-50 (BSL2 Renewal)

GAG Sequencing

Primary Reviewer: Hugh Mason

The PI provided an overview of the disclosure and responded to questions posed by the committee members. The lab is conducting research on glycosaminoglycans as a method to modulate physiological processes. The following changes were administratively made to the disclosure:

- Unchecked section III-E-1 on the NIH Guidelines page.
- Added E. coli BL21 to the Bacteria, Yeasts, and Fungi Page.

Discussion confirmed that Biosafety Level 2 precautions, training, and personal protective equipment are appropriate as proposed. Based on committee discussion, the NIH Guidelines classification for this disclosure was determined to be sections III-E, III-F-1, and III-F-8, Appendices C-I and C-II. A motion was made to approve the disclosure as modified. The motion was seconded.

Total Vote: 8 Approved: 8 Opposed: 0 Abstained: 0 Recused: 0

DSouza SPROTO2025-32 (BSL2 New Disclosure)

Dsouza Lab Biosafety Protocol

Primary Reviewer: Chris Plaisier

The PI provided an overview of the disclosure and responded to questions posed by the committee members. The lab is conducting research on growth dynamics of bacterial cells in microbiomes. The following changes were administratively made to the disclosure:

- Checked sections III-D-2 and III-D-2-a on the NIH Guidelines page.

The committee requested the following items be completed to secure approval of the disclosure:

- Coordinate with EHS to complete a lab inspection.

Discussion confirmed that Biosafety Level 2 precautions, training, and personal protective equipment are appropriate as proposed. Based on committee discussion, the NIH Guidelines classification for this disclosure was determined to be sections III-D, III-D-1, III-D-1-a, III-D-2, III-D-2-a, III-F-1, and III-F-8, Appendix C-II. A motion was made to appoint a Designated Reviewer to ensure the changes requested by the committee are made. The motion was seconded.

Total Vote: 8 Approved: 8 Opposed: 0 Abstained: 0 Recused: 0

Additional Business:

Consent Agenda

The committee reviewed and acknowledged the consent agenda.

1. Biosafety Officer's Report

- The Biosafety Officer informed the committee that the Select Agent registration renewal was received on July 7, 2025, and is valid for three years.
- The Biosafety Officer provided the committee with a recap of lab inspection findings for the month of June.
- The Biosafety Officer reported that EHS is continuing to work on the Polio sample identification plan. All labs have been asked if they have Polio samples, three labs have destroyed samples, and one lab remains on campus with samples that fall under the PIM definition. The lab is coordinating with EHS to develop a containment plan.

2. Education Item: Global incidence and mortality of severe fungal disease

3. Education Item: NIH announces end to funding for animal-only studies

The meeting was adjourned at 2:31 pm. The next IBC Meeting will be held on August 14, 2025 at 1:30 pm.